Delving into the Latest Updates on Umbilical cord mesenchymal stem cells (University of Miami) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogeneic Umbilical Cord Tissue derived MSCs(University of Miami), UCMSCs(University of Miami)

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication-

Inactive Indication

COVID-19Endothelial dysfunctionInflammation+ [3]

Originator Organization

University of Miami

Active Organization-

Inactive Organization

University of Miami

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.

This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized).

Start Date12 Apr 2018

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Umbilical cord mesenchymal stem cells (University of Miami)

Login to view more data

100 Translational Medicine associated with Umbilical cord mesenchymal stem cells (University of Miami)

Login to view more data

100 Patents (Medical) associated with Umbilical cord mesenchymal stem cells (University of Miami)

Login to view more data

100 Deals associated with Umbilical cord mesenchymal stem cells (University of Miami)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	United States	University of Miami	25 Apr 2020
Respiratory Distress Syndrome, Adult	Phase 2	United States	University of Miami	25 Apr 2020
Endothelial dysfunction	Phase 2	United States	University of Miami	12 Apr 2018
Inflammation	Phase 2	United States	University of Miami	12 Apr 2018
Metabolic Syndrome	Phase 2	United States	University of Miami	12 Apr 2018
Respiratory Distress Syndrome, Acute	Phase 1	-	University of Miami	01 Oct 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03059355 (CERES, CTgov)	Phase 1/2	Metabolic Syndrome \| Inflammation \| Endothelial dysfunction	14	UCMSCs (Pilot Phase: Group 1 (UCMSCs - 20 Million))	nlrhlmetzp = raotvnyqgb jvryyxlhlh (htscgenrsg, lwghvgbkjj - hsuaixgzmj) View more	-	08 Nov 2022
				BMMSCs (Pilot Phase: Group 2 (BMMSCs - 20 Million))	nlrhlmetzp = kynnalpork jvryyxlhlh (htscgenrsg, qztfpqftku - qoqryrckac) View more
NCT04355728 (CTgov)	Phase 1/2	COVID-19 \| Respiratory Distress Syndrome, Adult	24	Umbilical Cord Mesenchymal Stem Cells + Heparin along (UC-MSCs Group)	falvmygure = mffsqbycbt pogglpwdvd (zledwpgxov, juanmbnlaf - gvgbtopkli) View more	-	06 Dec 2021
				Vehicle + Heparin along with best supportive care (Control Group)	falvmygure = ioflylarzx pogglpwdvd (zledwpgxov, sdsbbqdukk - gytyfpzeoy) View more